MAPLE GROVE, Minn., March 11, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), a privately held, specialty pharmaceutical company committed to the development of new treatments for diseases of the central nervous system (CNS), is proud to sponsor emerging data for three investigational drug programs in epilepsy at the 65th Annual Meeting of the American Academy of Neurology (AAN) in San Diego, CA, March 16-23, 2013.
Upsher-Smith's CNS pipeline consists of two Phase III programs: USL255 (topiramate), an investigational extended-release topiramate for the management of epilepsy in adults; and USL261 (midazolam) for the intranasal rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity, often called seizure clusters. Additionally, USL260 (tonabersat) is a potential first-in-class neuronal gap junction modulator in Phase I of development for treatment of epilepsy.
"Upsher-Smith is committed to improving the lives of people living with epilepsy by developing innovative treatments to address the unmet needs of those who suffer from this condition," said William Pullman, MB BS, BMedSc, PhD, FRACP, Chief Scientific Officer, Upsher-Smith. "We are very pleased with the progress that has been made with each of our investigational CNS drug programs and are excited to share our ongoing scientific research in epilepsy at AAN's Annual Meeting."
Upsher-Smith sponsored posters include:
Single, High Doses of USL255, an Extended-Release Topiramate Formulation, Are Well Tolerated and Demonstrate a Dose-Proportional Pharmacokinetic Profile in Healthy Subjects Poster 04.212; Session P04: Epilepsy: Antiepileptic Medications: Special Populations and Pharmacokinetics; Wednesday, March 20, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m.
Safety and Pharmacodynamics of USL261, a Novel Formulation of Midazolam Optimized for Intranasal Administration P02.211; Session P02: Epilepsy: Novel Therapeutics and Basic Science; Tuesday, March 19, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m.
Pharmacokinetics of USL261, a Novel Formulation of Intranasal Midazolam Poster 02.212; Session P02: Epilepsy: Novel Therapeutics and Basic Science; Tuesday, March 19, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m.
Tonabersat, a Novel Investigational Anti-Seizure Drug, Inhibits Seizures in Models of Generalized Epilepsy Poster 02.209; Session P02: Epilepsy: Novel Therapeutics and Basic Science; Tuesday, March 19, 2013, 7:30 a.m. - 12:00 p.m. (Pacific Time); Authors Present 7:30 a.m. To schedule an interview with an investigator, please contact Elizabeth Likly at firstname.lastname@example.org.
Epilepsy is a medical condition that causes seizures affecting a variety of cognitive and physical functions. More than two million people in the U.S. are estimated to be affected by epilepsy with about 200,000 new cases of epilepsy diagnosed each year.1
Upsher-Smith, founded in 1919, is an independent and privately-owned specialty pharmaceutical company headquartered in Maple Grove, Minnesota that focuses on product growth and innovation for branded, branded-generic and generic pharmaceuticals. Upsher-Smith has a particular focus on providing therapies to assist people suffering from central nervous system diseases (including epilepsy, Parkinson's disease and Alzheimer's disease) and also markets products relating to cardiology, dermatology and women's health. In addition to products currently marketed, Upsher-Smith has an emerging neurology pipeline with three products in clinical development, two of which are in Phase III clinical trials. For more information, visit www.upsher-smith.com.
1. Epilepsy Foundation. About Epilepsy. Available at: http://www.epilepsyfoundation.org/aboutepilepsy/whatisepilepsy/statistics.cfm. Accessed February 4, 2013.
|SOURCE Upsher-Smith Laboratories, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
Related medicine technology :
1. Innophos CFO To Present At 2013 Sidoti Emerging Growth Conference
2. Frost & Sullivan Recognizes Cytomedix for its Pioneering System that Supports the Emerging Regenerative Therapies Market
3. Emerging Pharmaceutical Market in South Africa - Proposed Introduction of New Drug Regulatory Agency (SAHPRA) to Accelerate Drug Registration Process
4. The 113th Canton Fair: "Great Opportunities for Emerging Markets"
5. Emerging Growth Pharmaceutical Company Creates Gravitational Pull Towards Their Products
6. Cumberland Emerging Technologies Expands Life Sciences Center
7. Innovative CA Tumor Marker Tests Technologies and Emerging Markets
8. Emerging Data on USL261 (Intranasal Midazolam) to Be Presented at the 66th Annual Meeting of the American Epilepsy Society
9. Innovative Hematology and Flow Cytometry Technologies and Emerging Markets
10. Henry Schein Announces Featured Speakers For The "Recovery Empowerment Symposium: Emerging From The Storm"
11. Cepheid Announces Executive Vice President Emerging Markets
(Date:6/23/2016)... MedSource announced today that it has selected ... of choice. This latest decision demonstrates MedSource,s commitment ... clients by offering a state-of-the-art electronic data capture ... as the EDC platform of choice in exchange ... has long been a preferred EDC platform by ...
(Date:6/23/2016)... 23, 2016 In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... , June 23, 2016 Research and ... News Issue 52" report to their offering. ... influenza treatment creates a favourable commercial environment for MedImmune to ... patient base that will serve to drive considerable growth for ... would serve to cap sales considerably, but development is still ... Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... to revolutionize the emergency ambulance transport experience for the millions of people who ... Uber has disrupted the taxi industry through the use of technology. Now, SmartEMS ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of ... award to iHire in recognition of their exemplary accomplishments in worksite health promotion. , ... Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was ... his family verbally and physically. , “When something upset him, he couldn’t control his emotions,” ... He would throw rocks at my other children and say he was going to kill ... Breaking Medicine News(10 mins):